Hepatitis C SIG: HCV Treatment in Persons Who Inject Drugs
Recorded On: 10/20/2017
As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.
Mark W. Russo
Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. At the American Association for the Study of Liver Diseases, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine. He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.
Camilla S. Graham
John W. Ward
John W. Ward, MD created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health. He received his medical training at the University of Alabama at Birmingham and University of Washington and currently is a Professor in the Hubert Department of Global Health, Rollins School of Public Health, Emory University. Dr. Ward is an advisor to WHO Geneva, PAHO, WPRO, and the African Union. Dr. Ward chairs the AASLD Task Force for Hepatitis Elimination. Over a 13-year tenure, Dr. Ward directed the US CDC Division of Viral Hepatitis including hepatitis surveillance, prevention, and research. At the national level, Dr. Ward developed recommendations for hepatitis A and hepatitis B vaccination, hepatitis B and hepatitis C screening, and authored the first national action plan for hepatitis prevention. Dr. Ward guided the launch of pioneer HCV elimination programs. Previously, Dr. Ward led US HIV/AIDS surveillance. Ward has authored over 150 scientific publications.
Alain H. Litwin
Christian B. Ramers
Diana Sylvestre
Natasha Martin
